Examples of using Anagrelide in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
inhibitors like cilostazol or anagrelide.
Limited pharmacokinetic and/ or pharmacodynamic studies investigating possible interactions between anagrelide and other medicinal products have been conducted.
there is no evidence for anagrelide accumulation in the plasma.
such as cilostazol or anagrelide.
tolerability and safety of anagrelide hydrochloride versus hydroxyurea in high-risk patients with essential thrombocythaemia.
interferon/pegylated interferon(11.7%), anagrelide(7.2%), pipobroman(1.8%)
with the exception of hydroxyurea and/or anagrelide.
Shire will provide an annual update of all published data concerning the efficacy and safety of anagrelide in ET patients as part of the Annual Reassessment.
Understood although it has been confirmed that anagrelide is platelet selective from in vitro and in vivo study information.
Anagrelide should only be used if the potential benefits of therapy outweigh the potential risks.
Xagrid should not be used in people who may be hypersensitive(allergic) to anagrelide or any of the other ingredients.
The effects of food on bioavailability are not considered clinically relevant to the use of anagrelide.
10 adolescents) with anagrelide treatment.
Shire will provide an annual update of all published data concerning the efficacy and safety of anagrelide in ET patients alongside the annual PSURs(years 1 to 4 post-approval) and as part.
A clinical interaction study performed in healthy subjects showed that co-administration of repeat-dose anagrelide 1 mg once daily
in 8 children and 10 adolescents(including patients who were anagrelide treatment naïve or who had been receiving anagrelide for up to 5 years pre-study),
The most commonly reported adverse reactions associated with anagrelide were headache occurring at approximately 14%,
Very limited data are available on the use of anagrelide in the paediatric population and anagrelide should be used in this patient group with caution see sections 4.2,
different dose titration step to achieve an individual patient-optimised anagrelide regimen.
The specific mechanism of action by which anagrelide reduces platelet count is not yet fully understood although it has been confirmed that anagrelide is platelet selective from in vitro and in vivo study information.